Advertisement
Advertisement
U.S. Markets close in 1 hr 43 mins
Advertisement
Advertisement
Advertisement
Advertisement

Arrowhead Pharmaceuticals, Inc. (ARWR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
33.50+0.22 (+0.66%)
As of 02:15PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close33.28
Open33.29
Bid33.60 x 800
Ask33.62 x 800
Day's Range33.21 - 34.06
52 Week Range26.81 - 56.25
Volume181,382
Avg. Volume1,014,980
Market Cap3.502B
Beta (5Y Monthly)1.46
PE Ratio (TTM)N/A
EPS (TTM)-1.00
Earnings DateJan 31, 2023 - Feb 06, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est73.92
  • Business Wire

    Arrowhead Pharmaceuticals to Webcast Fiscal 2023 First Quarter Results

    PASADENA, Calif., January 25, 2023--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 6, 2023, at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 first quarter ended December 31, 2022.

  • Simply Wall St.

    A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

    Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Arrowhead...

  • Zacks Small Cap Research

    ARWR: Encouraging Results for Phase 2 SEQUOIA Trial…

    By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT On January 9, 2023, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced topline results for the Phase 2 SEQUOIA trial of fazirsiran (TAK-999/ARO-AAT) for the treatment of alpha-1 antitrypsin deficiency (AATD) liver disease. A copy of the slides discussing the results can be found here . The SEQUOIA trial is a placebo

Advertisement
Advertisement